{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:30:09Z","timestamp":1788877809878,"version":"build-2803163510"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19548, 24K02475"],"award-info":[{"award-number":["25K19548, 24K02475"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for various hematologic malignancies. Separation of graft-versus-leukemia (GVL) effects from graft-versus-host disease (GVHD) remains one of the central challenges in allo-HCT. However, relapse after allo-HCT remains associated with poor prognosis, and effective strategies that preserve graft-versus-leukemia (GVL) effects while preventing graft-versus-host disease (GVHD) are still lacking. Recent advances have revealed that post-transplant relapse is driven by diverse mechanisms, including leukemia-intrinsic immune escape, donor T-cell exhaustion, and persistence of leukemia stem cells. Emerging therapeutic strategies, such as selective modulation of T-cell trafficking and enhancement of tissue tolerance, are promising approaches to ameliorate GVHD without attenuating GVL effects. Additional approaches including cellular therapies, selective immune modulation, and restoration of leukemia immunogenicity are also being actively explored. Furthermore, restoration of leukemia immunogenicity and targeted elimination of leukemia stem cells are expected to provide new opportunities to prevent relapse without aggravating GVHD. In addition, approaches that reshape the tumor immune microenvironment or modulate T-cell exhaustion may further strengthen GVL activity while limiting harmful alloreactivity. These developments suggest that the long-considered difficult goal of separating GVHD from GVL effects may become achievable in the near future. In this review, we provide an overview of novel therapeutic targets aimed at achieving the separation of GVHD and GVL, with a particular focus on findings related to acute myeloid leukemia.<\/jats:p>","DOI":"10.3389\/fonc.2026.1838922","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:54:07Z","timestamp":1780030447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuta","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine","place":["Sapporo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine","place":["Sapporo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine","place":["Sapporo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101476","article-title":"Graft versus leukemia in 2023","volume":"36","author":"Chiad","year":"2023","journal-title":"Best Pract Res Clin Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365189","article-title":"Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia","volume":"118","author":"Katagiri","year":"2011","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00356.x","article-title":"Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts","volume":"98","author":"Masuda","year":"2007","journal-title":"Cancer Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000005","article-title":"Clonal evolution and immune evasion in posttransplantation relapses","volume":"2019","author":"Vago","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","article-title":"Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia","volume":"1","author":"Quek","year":"2016","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.285","article-title":"Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT","volume":"50","author":"Hamdi","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3916","article-title":"Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice","volume":"120","author":"Asakura","year":"2010","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci41446","article-title":"Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation","volume":"120","author":"Flutter","year":"2010","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016926","article-title":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","volume":"140","author":"Vallet","year":"2022","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0921","article-title":"BCL2 inhibition by venetoclax: Targeting the Achilles' heel of the acute myeloid leukemia stem cell","volume":"6","author":"Pullarkat","year":"2016","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1038\/s41467-019-12983-z","article-title":"Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection","volume":"10","author":"Caiado","year":"2019","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cas.16431","article-title":"TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation","volume":"116","author":"Sakoda","year":"2025","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological Malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701319","article-title":"High incidence of extramedullary relapse of AML after busulfan\/cyclophosphamide conditioning and allogeneic stem cell transplantation","volume":"22","author":"Simpson","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood.2025029121","article-title":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis","volume":"147","author":"Penter","year":"2026","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792614","article-title":"Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease","volume":"131","author":"Takahashi","year":"2018","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02181-3","article-title":"Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD","volume":"59","author":"Hudda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jtct.2023.12.019","article-title":"Phase 2 trial of ruxolitinib cream for chronic cutaneous GvHD","volume":"30","author":"Markova","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ni879","article-title":"Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction","volume":"4","author":"Murai","year":"2003","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.immuni.2019.06.003","article-title":"T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation","volume":"51","author":"Fu","year":"2019","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000002166","article-title":"Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease","volume":"33","author":"Innocenti","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0733-8","article-title":"Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis","volume":"55","author":"Yokoyama","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636123","article-title":"FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease","volume":"37","author":"Hashimoto","year":"2007","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci16950","article-title":"Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720","volume":"111","author":"Kim","year":"2003","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104719","article-title":"Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation","author":"Dertschnig","year":"2023","journal-title":"Cell Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740431","article-title":"Tissue tolerance: a distinct concept to control acute GVHD severity","volume":"129","author":"Wu","year":"2017","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101559","article-title":"The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells","volume":"208","author":"Takashima","year":"2011","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.05.028","article-title":"Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease","volume":"37","author":"Hanash","year":"2012","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170418","article-title":"R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease","volume":"214","author":"Hayase","year":"2017","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023060","article-title":"GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner","volume":"144","author":"Hasegawa","year":"2024","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.1038\/s41598-018-29100-7","article-title":"Intestinal lymphatic endothelial cells produce R-Spondin3","volume":"8","author":"Ogasawara","year":"2018","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay8556","article-title":"T cell-derived interferon-gamma programs stem cell death in immune-mediated intestinal damage","volume":"4","author":"Takashima","year":"2019","journal-title":"Sci Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature16460","article-title":"Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration","volume":"528","author":"Lindemans","year":"2015","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005957","article-title":"Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans","volume":"136","author":"Norona","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.080","article-title":"Use of teduglutide in the management of gastrointestinal graft-versus-host disease in children and young adults","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02586-2","article-title":"Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey","volume":"60","author":"Brehm","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012091","article-title":"Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis","volume":"8","author":"Akahoshi","year":"2024","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature24271","article-title":"Inflammatory memory sensitizes skin epithelial stem cells to tissue damage","volume":"550","author":"Naik","year":"2017","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07187-5","article-title":"Disease-associated astrocyte epigenetic memory promotes CNS pathology","volume":"627","author":"Lee","year":"2024","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.stem.2024.08.006","article-title":"Inflammation-induced epigenetic imprinting regulates intestinal stem cells","volume":"31","author":"Zhao","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028197","article-title":"Inflammatory memory of stem cells: implications for hematologic diseases","volume":"146","author":"Zhao","year":"2025","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2024-202926","article-title":"Gvhd-induced inflammatory memory in intestinal stem cells enhances IFN-\u03b3-induced antigen presentation and apoptosis of intestinal epithelial cells","volume":"144","author":"Miyajima","year":"2024","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104498","article-title":"Epigenetic-modifying agents: the potential game changers in the treatment of hematologic Malignancies","volume":"204","author":"Hojjatipour","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2025","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026916","article-title":"Sequential epigenetic therapy in AML","volume":"145","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/343275a0","article-title":"Identification of classical minor histocompatibility antigen as cell-derived peptide","volume":"343","author":"Wallny","year":"1990","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1034\/j.1600-065x.2002.19007.x","article-title":"The immunogenomics of minor histocompatibility antigens","volume":"190","author":"Roopenian","year":"2002","journal-title":"Immunol Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.1695760","article-title":"Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y","volume":"249","author":"Rotzschke","year":"1990","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/jci19427","article-title":"Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model","volume":"112","author":"Jones","year":"2003","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01163","article-title":"H60: a unique murine hematopoietic cell-restricted minor histocompatibility antigen for graft-versus-leukemia effect","volume":"11","author":"Choi","year":"2020","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-410","article-title":"In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens","volume":"8","author":"Dickinson","year":"2002","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199408150-00004","article-title":"Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation","volume":"58","author":"Korngold","year":"1994","journal-title":"Transplantation"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/89907","article-title":"Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease","volume":"7","author":"Fontaine","year":"2001","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/bf02983796","article-title":"Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation","volume":"78","author":"Mutis","year":"2003","journal-title":"Int J Hematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02348-3","article-title":"Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation","volume":"43","author":"Cieri","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.012","article-title":"Azacitidine post-transplant maintenance improves disease progression in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Pasvolsky","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2025029712","article-title":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","volume":"147","author":"Fetsch","year":"2026","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-368076","article-title":"The interferon-dependent orchestration of innate and adaptive immunity after transplantation","volume":"119","author":"Robb","year":"2012","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2513","article-title":"RIG-I\/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury","volume":"9","author":"Fischer","year":"2017","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838193","article-title":"Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease","volume":"132","author":"Swimm","year":"2018","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0925-5710(97)00081-9","article-title":"Interferon-alpha treatment of acute lymphoblastic leukemia relapse after unrelated bone marrow transplantation","volume":"67","author":"Nagafuji","year":"1998","journal-title":"Int J Hematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0692","article-title":"Interferon-alpha is effective for treatment of minimal residual disease in patients with t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: results of a prospective registry study","volume":"23","author":"Mo","year":"2018","journal-title":"Oncologist"},{"key":"B85","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2024-201237","article-title":"Ropeginterferon alfa-2b induces apoptosis and differentiation of leukemia stem cells and separates GVL effects from Gvhd after allogeneic hematopoietic cell transplantation","volume":"144","author":"Saito","year":"2024","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283437","article-title":"Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase","volume":"109","author":"Jeyaraju","year":"2024","journal-title":"Hematologica"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101664","article-title":"Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial","volume":"61","author":"Liu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06342-w","article-title":"The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"104","author":"Luo","year":"2025","journal-title":"Ann Hematol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41419-023-05728-w","article-title":"Type I interferon signaling in Malignant blasts contributes to treatment efficacy in AML patients","volume":"14","author":"Holicek","year":"2023","journal-title":"Cell Death Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02642-2","article-title":"KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML","volume":"39","author":"Zou","year":"2025","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387977","article-title":"Contrasting acute graft-versus-host disease effects of Tim-3\/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells","volume":"120","author":"Veenstra","year":"2012","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4281","article-title":"Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease","volume":"177","author":"Oikawa","year":"2006","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06550.x","article-title":"TIM-3 as a therapeutic target for Malignant stem cells in acute myelogenous leukemia","volume":"1266","author":"Kikushige","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e13","article-title":"Out-sourcing for trans-presentation: Assessing T cell intrinsic and extrinsic IL-15 expression with Il15 gene reporter mice","volume":"18","author":"Park","year":"2018","journal-title":"Immune Netw"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019875","article-title":"Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT","volume":"142","author":"Senjo","year":"2023","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e170125","DOI":"10.1172\/jci170125","article-title":"Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD","volume":"134","author":"Wang","year":"2024","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood-2024-197873","article-title":"Early initiation of calcineurin inhibitor induces CD8 + transitory exhausted-like and CD4 + cytotoxic T cells, maintaining responsiveness to PD-1 blockade and contributing to the development of chronic Gvhd after post-transplant cyclophosphamide","volume":"144","author":"Senjo","year":"2024","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.962","article-title":"Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation","volume":"5","author":"Terao","year":"2024","journal-title":"EJHaem"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of gammadelta T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.558143","article-title":"Donor gammadeltaT cells promote GVL effect and mitigate aGVHD in allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci Transl Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70096","article-title":"Selection and characterization of minor histocompatibility antigen-specific regulatory T cells in fully HLA-matched setting for GVHD therapy","volume":"55","author":"Pacini","year":"2025","journal-title":"Eur J Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1838922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:54:11Z","timestamp":1780030451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1838922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":109,"alternative-id":["10.3389\/fonc.2026.1838922"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1838922","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1838922"}}